IL-13

Interleukin-13 (IL-13) is a type 2 cytokine primarily produced by Th2 cells, regulating immune responses through modulation of macrophage and epithelial cell activity^[1]. Mechanistically, IL-13 signals via the IL-4 receptor alpha (IL-4Rα)/IL-13Rα1 heterodimer, activating the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, particularly STAT6, to induce gene expression associated with allergic inflammation and tissue remodeling^[2][3]. In disease models such as experimental autoimmune encephalomyelitis (EAE), IL-13 exerts anti-inflammatory effects by suppressing Th1 and Th17-mediated neuroinflammation, highlighting its role in immune regulation and potential neuroprotective function^[4][5]. Compared with related isoforms like IL-4, IL-13 demonstrates distinct receptor-binding affinities and downstream signaling kinetics, which influence the magnitude and specificity of cellular responses^[6]. Pharmacological agonists of IL-13 or IL-13R pathways have been employed experimentally to modulate immune cell polarization and cytokine production, whereas IL-13 neutralizing antibodies are utilized to dissect isoform-specific effects in inflammatory models^[7][8]. These experimental applications provide insight into IL-13’s selective regulation of immune pathways, offering mechanistic understanding and design considerations for cytokine-targeted interventions in autoimmune and allergic diseases^[9].